Key Highlights

  • Full-year Revenue guidance was raised in July 2026 to at least £8.0m, implying growth of about 22%.
  • Interim revenue rose 23% to £3.9m, with the contracted order book up 38% to £18.1m.
  • Two Huntington's disease clinical programmes were cancelled, trimming the order book by roughly £1.5m over two years.
  • A £10m Capital raise lifted pro-forma cash to roughly £11.1m.
  • Shares slipped below their 50-day and 200-day moving averages despite reaffirmed guidance.

IXICO (LSE:IXI), the AIM-quoted neuroscience imaging and biomarker analytics group, lifted its full-year revenue guidance in July to at least 8.0 million pounds, implying growth of roughly 22%, yet its shares have since slipped back below both their 50-day and 200-day moving averages. The stock, which leapt almost 16% on the day of the upgrade to 9.4p, was changing hands at around 7.5p by early August, valuing the company at about 16.4 million pounds. The pullback followed the cancellation of two Huntington's disease trials and came despite management reaffirming its raised forecasts. With the Business still loss-making at the operating line but freshly capitalised after a 10 million pound placing, the recent share-price weakness looks more like profit-taking and dilution overhang than a verdict on trading.

What happened?

On 7 July 2026 IXICO issued a trading update that raised expectations for the year to 30 September. The company said revenue would be at least 8.0 million pounds, up from its previous guidance of about 7.5 million pounds and equivalent to growth of roughly 22%, against the 15% it had signalled only weeks earlier. Chief executive Bram Goorden attributed the upgrade to a continued uplift in contract wins, contract extensions and revenue diversification, the fruits of a strategy reset begun in 2024. The market cheered the news: the shares jumped 15.69% to 9.4p on the day.

The mood cooled the following week. On 13 July the company disclosed that two Huntington's disease clinical programmes had been cancelled, trimming the contracted order book by roughly 1.5 million pounds spread over the next two financial years. Crucially, IXICO reaffirmed its upgraded guidance for both 2026 and 2027, pointing to 8.0 million pounds of new Huntington's-related awards secured in the first half and an order book still running 21% higher than a year earlier.

Despite the reassurance, the shares have drifted. By 9 August the stock had fallen to about 7.5p, slipping beneath its 200-day Moving Average of 8.28p and its 50-day average of 8.37p. No single adverse announcement obviously explains the August weakness, so the precise trigger for the decline is unclear. The most plausible explanations are profit-taking after the sharp July spike and a lingering overhang from a recent Equity raise, rather than any deterioration in the underlying order book.

The numbers investors need to know

The interim results, published on 19 May 2026 for the six months to 31 March, set the tone. Revenue rose 23% to 3.9 million pounds, driven by new contract wins, extensions and a higher Volume of biomarker analyses. The contracted order book swelled 38% year on year to 18.1 million pounds, from 13.1 million pounds, a multi-year high. Gross Margin improved to 53% from 50%, and the EBITDA loss narrowed to 0.5 million pounds from 0.7 million pounds.

Cash stood at just 1.7 million pounds at the half-year, down from 5.0 million pounds a year earlier, but the Balance Sheet was transformed shortly afterwards by a 10 million pound capital raise that lifted pro-forma cash to roughly 11.1 million pounds. That fundraise dilutes existing holders but removes near-term financing risk.

The subsequent July upgrade pushed full-year guidance to at least 8.0 million pounds, around 22% growth. Set against that, the Huntington's cancellations cost about 1.5 million pounds of order book over two years. At 7.5p the shares carry a Market Capitalisation of about 16.4 million pounds. There is no dividend, and the group remains loss-making at the operating level with negative operating cash flow.

Why the market may be concerned

IXICO is a sub-20 million pound micro-cap that has yet to prove it can turn rising revenue into sustained profit. Even after the upgrade the business is loss-making and burning cash, and the July spike left the shares looking technically overbought, a set-up that often invites a pullback.

The Huntington's cancellations are a reminder of the model's inherent fragility. As a specialist imaging contract research organisation, IXICO depends on the funding decisions of pharmaceutical and biotech sponsors whose trials can be paused or scrapped at short notice, taking booked order book with them.

The 10 million pound placing, while sensible given the thin half-year cash balance, dilutes existing shareholders and may weigh on the shares as placees settle in. Add wafer-thin trading Liquidity and the absence of any income, and the stock remains firmly in speculative territory.

Why bulls may see an opportunity

The direction of travel on trading is unambiguously positive. Two guidance upgrades in quick succession, 23% first-half revenue growth and an order book up 38% to a multi-year high all point to genuine commercial momentum rather than one-off wins.

Diversification is reducing single-programme risk. The fact that IXICO won 8.0 million pounds of fresh Huntington's work even as two studies were cancelled shows the pipeline can absorb setbacks, and Demand tied to Alzheimer's and other neurodegenerative trials remains structurally strong.

With roughly 11.1 million pounds of pro-forma cash the company has runway to invest in its AI-driven platform without an immediate return to the market. Broker Cavendish has reportedly characterised the forecasts as conservative after the order book reached a five-year high, suggesting scope for further upgrades if conversion holds.

What happens next?

The key event is the full-year result for the year to 30 September, which will test whether the group hits or beats its at-least-8.0 million pound target. Investors will focus on order-book conversion, the pace of cash consumption and any progress toward EBITDA breakeven.

Beyond the headline numbers, the flow of new contract awards and any further trial cancellations will drive sentiment in a stock where the order book is the single most-watched metric. Evidence that the diversified pipeline can keep growing despite individual programme risk would support the bull case.

For now the shares are consolidating well below their July peak. A clear catalyst, most likely fresh contract news or confirmation of the full-year outcome, will be needed to re-establish an uptrend.

Outlook

The original framing had IXICO (LSE:IXI) tumbling in the wake of its 22% growth forecast, but the market's first reaction was the opposite: the shares jumped almost 16% on the upgrade. The subsequent drift back to around 7.5p looks like profit-taking, dilution from a 10 million pound placing and some read-across from the cancelled Huntington's trials, rather than any deterioration in trading, which management reaffirmed. IXICO remains a speculative, loss-making micro-cap whose Investment case rests on converting a swelling pipeline into durable profit. The fundamentals are improving even as the share price cools, and the precise trigger for the August weakness is not clearly identifiable in the news flow. Patient investors will want proof of the path to breakeven before the rating re-rates.